drugset / Trial / NCT05766527
A Study of KM602 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and activity of KM602 as monotherapy in patients with advanced solid tumors.
Timeline
- Start
- 2023-04
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KM602 | Unknown | 0.01 mg/kg | Intravenous |
| Subject | KM602 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | KM602 | Unknown | 0.6 mg/kg | Intravenous |
| Subject | KM602 | Unknown | 3 mg/kg | Intravenous |
| Subject | KM602 | Unknown | 10 mg/kg | Intravenous |